MATRIX Technology Accelerator Domain 1
Seed Grants for HIV Prevention Products
RFA2024-003

Fact-finding questions and responses

The MATRIX team thanks applicants who expressed interest in submitting a response to this Request for Application (RFA).

As a reminder, full applications are due by 8:00 AM Pacific time on April 1, 2024, and applicants should be from institutions in the United States, European Union, United Kingdom, Kenya, South Africa, and Zimbabwe. Applicants should ensure that their application describes the development of new primary HIV prevention drugs, delivery technologies, or diagnostics. Refer to the RFA for more details on responsive and non-responsive areas of research.

Please [refer to the RFA](#) for additional information or reach out to the PATH team at MatrixTechAcceleratorRFA@path.org.

Fact-finding questions from applicants and responses:

1. What is the prescription for the budget allocation? The research activities planned will be conducted between institutes across two continents. Is there any guidance on budget allocation between the two institutes?
   There is no prescribed allocation for dividing the project funds between the partnering institutions. The proposed budget for each institution should match the scope of work to be conducted there. Any end-user research must be 25 percent or less of the research budget. Details on budget requirements can be found in the RFA instructions and the budget templates that are linked above.

2. What is the process, or who can we liaise with at PATH throughout the development of the application (especially the budget) to verify budget-related queries?
   All questions related to the application can be sent to MatrixTechAcceleratorRFA@path.org. In order to be fair and consistent with all applicants, we may not be able to address specific questions about your application.